{"title_page": "Ranpirnase", "text_new": "{{Infobox nonhuman protein\n| Name = Ranpirnase\n| image = 2I5S.png\n| width =\n| caption = [[Crystallography|Crystallographic]] structure of ranpirnase in complex with RNA.<ref>{{cite journal | vauthors = Lee JE, Bae E, Bingman CA, Phillips GN, Raines RT | title = Structural basis for catalysis by onconase | journal = Journal of Molecular Biology | volume = 375 | issue = 1 | pages = 165\u201377 | date = January 2008 | pmid = 18001769 | pmc = 2151974 | doi = 10.1016/j.jmb.2007.09.089 }}</ref>\n|  Organism = Rana pipiens\n| TaxID = 8404\n| Symbol = n/a\n| AltSymbols =\n| IUPHAR_id =\n| ATC_prefix =\n| ATC_suffix =\n| ATC_supplemental =\n| CAS_number =\n| CAS_supplemental =\n| DrugBank =\n| EntrezGene =\n| PDB = 2I5S\n| RefSeqmRNA =\n| RefSeqProtein =\n| UniProt = P85073\n| ECnumber = 3.1.27\n| Chromosome =\n| EntrezChromosome =\n| GenLoc_start =\n| GenLoc_end =\n}}\n'''Ranpirnase''' is a [[ribonuclease]] [[enzyme]] found in the [[oocytes]] of the [[Northern Leopard Frog]] (''Rana pipiens''). Ranpirnase is a member of the [[pancreatic ribonuclease]] (RNase A) protein superfamily and degrades [[RNA]] [[substrate (chemistry)|substrates]] with a [[RNA sequence|sequence]] preference for [[uracil]] and [[guanine]] [[nucleotide]]s. Along with [[amphinase]], another leopard frog ribonuclease, Ranpirnase has been studied as a potential [[cancer]] and antiviral treatment due to its unusual mechanism of [[cytotoxicity]] tested against [[tumor|transformed]] cells and antiviral activity.<ref name=\"ardelt\">{{cite journal | vauthors = Ardelt W, Shogen K, Darzynkiewicz Z | title = Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes | journal = Current Pharmaceutical Biotechnology | volume = 9 | issue = 3 | pages = 215\u201325 | date = June 2008 | pmid = 18673287 | pmc = 2586917 | doi = 10.2174/138920108784567245 }}</ref>\n\nRanpirnase was originally discovered by scientists at [http://www.tamirbio.com '''TamirBio'''], a [[biotechnology]] company (formerly Alfacell Corporation), where it was tested in preclinical assays<ref>Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent.Cell Tissue Kinet. 1988 May;21(3):169-82. {{PMID|3224365}}</ref> and in [[clinical trial]]s under the name ''Pannon'' or ''Onconase'', and ''TMR004''. The [[mechanism of action]] of ranpirnase has been attributed to the [[RNA interference]] pathway, potentially through cleaving [[siRNA]] molecules;<ref name=\"zhao\">{{cite journal | vauthors = Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z | title = The cytotoxic ribonuclease onconase targets RNA interference (siRNA) | journal = Cell Cycle | volume = 7 | issue = 20 | pages = 3258\u201361 | date = October 2008 | pmid = 18927512 | pmc = 2586937 | doi = 10.4161/cc.7.20.6855 }}</ref> to cleavage of [[transfer RNA]];<ref name=\"ardelt\" /> and to interference with the [[NFKB|NF-\u03baB]] pathway.<ref>{{cite journal | vauthors = Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H | title = Ranpirnase Interferes with NF-\u03baB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth | journal = Genes & Cancer | volume = 2 | issue = 5 | pages = 576\u201384 | date = May 2011 | pmid = 21901170 | pmc = 3161417 | doi = 10.1177/1947601911412375 }}</ref> Currently (as of March 2020) Ranpirnase is in clinical trials for as a potential [https://clinicaltrials.gov/ct2/show/NCT03856645?term=okogen&draw=2&rank=1 antiviral].<ref>OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis (RUBY) 2020 March 3. Phase 2. Drug: OKG-0301. {{NCT|03856645}}.</ref>\n\n== References ==\n{{reflist|32em}}\n{{Use dmy dates|date=April 2017}}\n\n[[Category:Ribonucleases]]\n[[Category:Experimental drugs]]\n\n{{Enzyme-stub}}\n", "text_old": "{{Infobox nonhuman protein\n| Name = Ranpirnase\n| image = 2I5S.png\n| width =\n| caption = [[Crystallography|Crystallographic]] structure of ranpirnase in complex with RNA.<ref>{{cite journal | vauthors = Lee JE, Bae E, Bingman CA, Phillips GN, Raines RT | title = Structural basis for catalysis by onconase | journal = Journal of Molecular Biology | volume = 375 | issue = 1 | pages = 165\u201377 | date = January 2008 | pmid = 18001769 | pmc = 2151974 | doi = 10.1016/j.jmb.2007.09.089 }}</ref>\n|  Organism = Rana pipiens\n| TaxID = 8404\n| Symbol = n/a\n| AltSymbols =\n| IUPHAR_id =\n| ATC_prefix =\n| ATC_suffix =\n| ATC_supplemental =\n| CAS_number =\n| CAS_supplemental =\n| DrugBank =\n| EntrezGene =\n| PDB = 2I5S\n| RefSeqmRNA =\n| RefSeqProtein =\n| UniProt = P85073\n| ECnumber = 3.1.27\n| Chromosome =\n| EntrezChromosome =\n| GenLoc_start =\n| GenLoc_end =\n}}\n'''Ranpirnase''' is a [[ribonuclease]] [[enzyme]] found in the [[oocytes]] of the [[Northern Leopard Frog]] (''Rana pipiens''). Ranpirnase is a member of the [[pancreatic ribonuclease]] (RNase A) protein superfamily and degrades [[RNA]] [[substrate (chemistry)|substrates]] with a [[RNA sequence|sequence]] preference for [[uracil]] and [[guanine]] [[nucleotide]]s. Along with [[amphinase]], another leopard frog ribonuclease, Ranpirnase has been studied as a potential [[cancer]] and antiviral treatment due to its unusual mechanism of [[cytotoxicity]] tested against [[tumor|transformed]] cells and antiviral activity.<ref name=\"ardelt\">{{cite journal | vauthors = Ardelt W, Shogen K, Darzynkiewicz Z | title = Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes | journal = Current Pharmaceutical Biotechnology | volume = 9 | issue = 3 | pages = 215\u201325 | date = June 2008 | pmid = 18673287 | pmc = 2586917 | doi = 10.2174/138920108784567245 }}</ref>\n\nRanpirnase was originally discovered by scientists at [http://www.tamirbio.com '''TamirBio'''], a [[biotechnology]] company (formerly Alfacell Corporation), where it was tested in preclinical assays<ref>Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent.Cell Tissue Kinet. 1988 May;21(3):169-82. {{PMID|3224365}}</ref> and in [[clinical trial]]s under the name ''Pannon'' or ''Onconase'', and ''TMR004''. The [[mechanism of action]] of ranpirnase has been attributed to the [[RNA interference]] pathway, potentially through cleaving [[siRNA]] molecules;<ref name=\"zhao\">{{cite journal | vauthors = Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z | title = The cytotoxic ribonuclease onconase targets RNA interference (siRNA) | journal = Cell Cycle | volume = 7 | issue = 20 | pages = 3258\u201361 | date = October 2008 | pmid = 18927512 | pmc = 2586937 | doi = 10.4161/cc.7.20.6855 }}</ref> to cleavage of [[transfer RNA]];<ref name=\"ardelt\" /> and to interference with the [[NFKB|NF-\u03baB]] pathway.<ref>{{cite journal | vauthors = Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H | title = Ranpirnase Interferes with NF-\u03baB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth | journal = Genes & Cancer | volume = 2 | issue = 5 | pages = 576\u201384 | date = May 2011 | pmid = 21901170 | pmc = 3161417 | doi = 10.1177/1947601911412375 }}</ref> Currently (as of March 2020) Ranpirnase is in clinical trials for as a potential antiviral.<ref>OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis (RUBY) 2020 March 3. Phase 2. Drug: OKG-0301. {{NCT|03856645}}.</ref>\n\n== References ==\n{{reflist|32em}}\n{{Use dmy dates|date=April 2017}}\n\n[[Category:Ribonucleases]]\n[[Category:Experimental drugs]]\n\n{{Enzyme-stub}}\n", "name_user": "Islandcollector", "label": "safe", "comment": "link", "url_page": "//en.wikipedia.org/wiki/Ranpirnase"}
